Evidence map›Paper›PMID 38085565›Full record

ArticleJMIR cancer2023

Exploring the Incorporation of a Novel Cardiotoxicity Mobile Health App Into Care of Patients With Cancer: Qualitative Study of Patient and Provider Perspectives.

Megan E Gregory, Weidan Cao, Saurabh Rahurkar, Pallavi Jonnalagadda, James C Stock, Sanam M Ghazi, Endia Reid, Abigail L Berk, Courtney Hebert, Lang Li and 1 more

Abstract read
In one paragraph

Article in JMIR cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. CardioAI: A Multimodal AI-based System to Support Symptom Monitoring and Risk Prediction of Cancer Treatment-Induced Cardiotoxicity.Proceedings of the SIGCHI conference on human factors in computing systems. CHI Conference · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Megan E GregoryDepartment of Health Outcomes and Biomedical Informatics, College of Medicine, Univeristy of Florida, Gainesville, FL, United States.ORCID https://orcid.org/0000-0002-6888-6886
Weidan CaoDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0001-5417-2121
Saurabh RahurkarDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0001-8597-3087
Pallavi JonnalagaddaThe Center for the Advancement of Team Science, Analytics, and Systems Thinking (CATALYST), College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0002-2322-3229
James C StockCardio-Oncology Program, Division of Cardiovascular Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0009-0009-7227-8494
Sanam M GhaziCardio-Oncology Program, Division of Cardiovascular Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0002-7205-1427
Endia ReidDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0009-0000-2466-2314
Abigail L BerkBiomedical Sciences Program, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0001-7508-2280
Courtney HebertDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0003-1646-702X
Lang LiDepartment of Biomedical Informatics, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0002-0746-1809
Daniel AddisonCardio-Oncology Program, Division of Cardiovascular Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID https://orcid.org/0000-0002-9113-8333

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Novel patient biomarkers and mechanisms of TKI associated CardiotoxicityR01HL170038 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Daniel Addison · 2023 to 2026
$2.7M
Early Detection and Mechanisms of Cancer Immunotherapy Associated CardiotoxicityK23HL155890 · NHLBI · OHIO STATE UNIVERSITY · PI ADDISON, DANIEL · 2021 to 2024
$663k
NCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NHLBI NIH HHS K23 HL155890NHLBI NIH HHS R01 HL170038
6 · The paper itself

Abstract

backgroundCardiotoxicity is a limitation of several cancer therapies and early recognition improves outcomes. Symptom-tracking mobile health (mHealth) apps are feasible and beneficial, but key elements for mHealth symptom-tracking to indicate early signs of cardiotoxicity are unknown.

objectiveWe explored considerations for the design of, and implementation into a large academic medical center, an mHealth symptom-tracking tool for early recognition of cardiotoxicity in patients with cancer after cancer therapy initiation.

methodsWe conducted semistructured interviews of >50% of the providers (oncologists, cardio-oncologists, and radiation oncologists) who manage cancer treatment-related cardiotoxicity in the participating institution (n=11), and either interviews or co-design or both with 6 patients. Data were coded and analyzed using thematic analysis.

resultsProviders indicated that there was no existing process to enable early recognition of cardiotoxicity and felt the app could reduce delays in diagnosis and lead to better patient outcomes. Signs and symptoms providers recommended for tracking included chest pain or tightness, shortness of breath, heart racing or palpitations, syncope, lightheadedness, edema, and excessive fatigue. Implementation barriers included determining who would receive symptom reports, ensuring all members of the patient's care team (eg, oncologist, cardiologist, and primary care) were informed of the symptom reports and could collaborate on care plans, and how to best integrate the app data into the electronic health record. Patients (n=6, 100%) agreed that the app would be useful for enhanced symptom capture and education and indicated willingness to use it.

conclusionsProviders and patients agree that a patient-facing, cancer treatment-related cardiotoxicity symptom-tracking mHealth app would be beneficial. Additional studies evaluating the role of mHealth as a potential strategy for targeted early cardioprotective therapy initiation are needed.

Indexed as

applicationcancer, cardiology, implementation science, mobile app, oncologycancer patientcancer therapycardiotoxicitydesigndevelopmentimplementationmobile health applicationmobile phonepatient careprimary caresymptomsymptom tracking

Identifiers

PMID38085565
PMCPMC10751627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.